생화학분자생물학회

	Name: Eui-Cheol Shin ( ecshin@kaist.ac.kr )
	2007-present	Assistant Professor, Associate Professor, and Professor, KAIST, Daejeon
	2002-2007	Postdoctoral Fellow, NIDDK, NIH, Bethesda, Maryland, USA
	1996-2001	Master & Ph.D. (in Microbiology/Immunology) Yonsei University, Seoul
	1990-1996	M.D. Yonsei University College of Medicine, Seoul
	Name: Hojun Choi ( hchoi@iliasbio.com )
	2021-present	Senior Researcher, ILIAS Biologics, Daejeon
	2015-2021	Master & Ph.D. Department of Bio and Brain Engineering, KAIST, Daejeon
	2011-2014	B.S. Department of Bio and Brain Engineering, KAIST, Daejeon

Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe COVID-19 exhibit hyper-inflammatory responses characterized by excessive activation of myeloid cells, including monocytes, macrophages, and neutrophils and a plethora of pro-inflammatory cytokines and chemokines. Accumulating evidence also indicates that hyper-inflammation is a driving factor for severe progression of the disease, which has prompted the development of anti-inflammatory therapies for the treatment of patients with COVID-19. Corticosteroids, IL-6R inhibitors, and JAK inhibitors have demonstrated promising results in treating patients with severe disease. In addition, diverse forms of exosomes that exert anti-inflammatory functions have been tested experimentally for the treatment of COVID-19. Here, we briefly describe the immunological mechanisms of the hyper-inflammatory responses in patients with severe COVID-19. We also summarize current anti-inflammatory therapies for the treatment of severe COVID-19 and novel exosome-based therapeutics that are in experimental stages.


BMB Rep. 2021 Dec 14;5488. [Online ahead of print]
https://pubmed.ncbi.nlm.nih.gov/34903319/